Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.

EP: 1.Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment

EP: 2.Metastatic Breast Cancer Treatment Guidelines and the Nuances of HER2-Low Disease in Clinical Practice

EP: 3.Transforming Breast Cancer Treatment Through ADC-Targeting Mechanisms

EP: 4.How ADC Design Influences Efficacy and Safety

EP: 5.Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer

EP: 6.Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer

EP: 7.Key Considerations for Oncology Pharmacists When Selecting and Sequencing ADC Therapies

EP: 8.Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment

EP: 9.Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies

EP: 10.Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care

EP: 11.Managing ADC Toxicities and Infusion Reactions With Supportive Care Strategies

EP: 12.Monitoring Strategies for Managing ADC Toxicities in mBC

EP: 13.Optimizing ADC Supportive Care Prescribing and AE Management With Institutional Workflows

EP: 14.Discussing ADC Risks, Benefits, and Regimens With Patients

Now Viewing

EP: 15.Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health

Video content above has been prompted by the following:

What interdisciplinary approaches to care can help optimize ADC therapy outcomes in patients with mBC?
Do patients receiving ADC therapy at your practice experience adherence barriers due to social determinants of health, treatment costs, accessibility, or insurance coverage?